Cytokinetics (CYTK) Stock: Charts & Financials

Cytokinetics, Incorporated(CYTK)

Biotechnology · South San Francisco, CA

$61.27-1.43 (-2.28%)

Delayed quote: Oct 6, 2026, 12:50 PM EDT

About Cytokinetics, Incorporated

Cytokinetics, Incorporated, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel muscle activators and muscle inhibitors as potential treatments for debilitating diseases in the United States. The company markets MYQORZO, a novel, oral, and small molecule cardiac myosin inhibitor for the treatment of symptomatic oHCM. It also develops Aficamten, a novel, oral, and small molecule cardiac myosin inhibitor for the treatment of HCM; and omecamtiv mecarbil, a potential treatment across the continuum of care in heart failure with severely reduced ejection fraction. In addition, the company is involved in developing and Ulacamten, a novel, selective, oral, and small molecule cardiac myosin inhibitor designed to reduce the hypercontractility associated with heart failure with preserved ejection fraction in Phase 1 clinical trials; and CK-089, a fast skeletal muscle troponin activator in Phase 1 clinical trials. Cytokinetics, Incorporated was incorporated in 1997 and is headquartered in South San Francisco, California.

South San Francisco, CA

673 employees

www.cytokinetics.com

Healthcare / Biotechnology

Sector: Healthcare
Industry: Biotechnology
CEO: Robert I. Blum

View full financials

Quarterly Report	TTM	Quarter ended Jun 2026	Quarter ended Mar 2026	Quarter ended Dec 2025	Quarter ended Sep 2025	Quarter ended Jun 2025	Quarter ended Mar 2025	Quarter ended Dec 2024	Quarter ended Sep 2024
Revenue	70.96M	31.91M	19.36M	17.75M	1.94M	66.77M	1.58M	16.93M	463K
Cost of Goods Sold	10.66M	2.73M	2.39M	2.86M	2.68M	2.29M	99.84M	93.63M	84.61M
Gross Profit	60.30M	29.18M	16.96M	14.89M	-743K	64.48M	-98.26M	-76.70M	-84.15M
Gross Profit Margin	85.0%	91.4%	87.6%	83.9%	-38.4%	96.6%	-6223.1%	-453.1%	-18174.7%
Total Operating Expenses	764.92M	205.06M	200.58M	193.26M	166.01M	175.99M	57.37M	62.34M	56.65M
Research & Development	394.10M	97.81M	95.53M	101.54M	99.23M	112.55M	99.84M	93.63M	84.61M
Selling, General & Administrative	370.47M	104.40M	104.90M	91.72M	69.46M	65.72M	57.37M	62.34M	56.65M
Operating Income (EBIT)	-704.62M	-175.88M	-183.62M	-178.37M	-166.75M	-111.51M	-155.63M	-139.04M	-140.80M
Operating Margin	-993.0%	-551.1%	-948.7%	-1004.6%	-8613.4%	-167.0%	-9856.3%	-821.4%	-30410.6%
Income Before Tax (EBT)	-894.00M	-198.76M	-206.03M	-183.03M	-306.18M	-134.37M	-161.38M	-150.02M	-160.54M
Interest Income	46.68M	13.94M	11.02M	11.47M	10.25M	13.00M	13.70M	15.01M	17.05M
Interest Expense	124.82M	34.83M	33.34M	30.34M	26.32M	24.27M	22.95M	22.59M	22.30M
Other Income/Expense	-189.38M	-22.88M	-22.41M	-4.67M	-139.42M	-22.86M	-5.75M	-10.98M	-19.74M
Net Income	-894.00M	-198.76M	-206.03M	-183.03M	-306.18M	-134.37M	-161.38M	-150.02M	-160.54M
Income Tax Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Net Profit Margin	-1259.9%	-622.8%	-1064.5%	-1030.9%	-15815.0%	-201.2%	-10220.1%	-886.3%	-34674.9%
EBITDA	-688.88M	-168.87M	-180.24M	-175.69M	-164.08M	-109.22M	-153.33M	-136.66M	-138.39M
EBITDA Margin	-970.8%	-529.2%	-931.2%	-989.5%	-8475.0%	-163.6%	-9710.6%	-807.3%	-29889.8%
Depreciation & Amortization	15.74M	7.01M	3.38M	2.68M	2.68M	2.29M	2.30M	2.38M	2.41M
EPS Basic	-7.21	-1.50	-1.67	-1.49	-2.55	-1.12	-1.36	-1.27	-1.36
EPS Diluted	-7.22	-1.50	-1.67	-1.50	-2.55	-1.12	-1.36	-1.27	-1.36
Weighted Average Basic Shares	132.09M	132.09M	123.27M	122.02M	119.98M	119.46M	118.50M	118.08M	117.69M
Weighted Average Diluted Shares	132.09M	132.09M	123.27M	122.43M	119.98M	119.46M	118.50M	118.08M	117.69M

Quarterly Report

TTM

Quarter ended Jun 2026

Quarter ended Mar 2026

Quarter ended Dec 2025

Quarter ended Sep 2025

Quarter ended Jun 2025

Quarter ended Mar 2025

Quarter ended Dec 2024

Quarter ended Sep 2024

Revenue

70.96M

31.91M

19.36M

17.75M

1.94M

66.77M

1.58M

16.93M

463K

Cost of Goods Sold

10.66M

2.73M

2.39M

2.86M

2.68M

2.29M

99.84M

93.63M

84.61M

Gross Profit

60.30M

29.18M

16.96M

14.89M

-743K

64.48M

-98.26M

-76.70M

-84.15M

Gross Profit Margin

85.0%

91.4%

87.6%

83.9%

-38.4%

96.6%

-6223.1%

-453.1%

-18174.7%

Total Operating Expenses

764.92M

205.06M

200.58M

193.26M

166.01M

175.99M

57.37M

62.34M

56.65M

Research & Development

394.10M

97.81M

95.53M

101.54M

99.23M

112.55M

99.84M

93.63M

84.61M

Selling, General & Administrative

370.47M

104.40M

104.90M

91.72M

69.46M

65.72M

57.37M

62.34M

56.65M

Operating Income (EBIT)

-704.62M

-175.88M

-183.62M

-178.37M

-166.75M

-111.51M

-155.63M

-139.04M

-140.80M

Operating Margin

-993.0%

-551.1%

-948.7%

-1004.6%

-8613.4%

-167.0%

-9856.3%

-821.4%

-30410.6%

Income Before Tax (EBT)

-894.00M

-198.76M

-206.03M

-183.03M

-306.18M

-134.37M

-161.38M

-150.02M

-160.54M

Interest Income

46.68M

13.94M

11.02M

11.47M

10.25M

13.00M

13.70M

15.01M

17.05M

Interest Expense

124.82M

34.83M

33.34M

30.34M

26.32M

24.27M

22.95M

22.59M

22.30M

Other Income/Expense

-189.38M

-22.88M

-22.41M

-4.67M

-139.42M

-22.86M

-5.75M

-10.98M

-19.74M

Net Income

-894.00M

-198.76M

-206.03M

-183.03M

-306.18M

-134.37M

-161.38M

-150.02M

-160.54M

Income Tax Expense

0.00

Net Profit Margin

-1259.9%

-622.8%

-1064.5%

-1030.9%

-15815.0%

-201.2%

-10220.1%

-886.3%

-34674.9%

EBITDA

-688.88M

-168.87M

-180.24M

-175.69M

-164.08M

-109.22M

-153.33M

-136.66M

-138.39M

EBITDA Margin

-970.8%

-529.2%

-931.2%

-989.5%

-8475.0%

-163.6%

-9710.6%

-807.3%

-29889.8%

Depreciation & Amortization

15.74M

7.01M

3.38M

2.68M

2.29M

2.30M

2.38M

2.41M

EPS Basic

-7.21

-1.50

-1.67

-1.49

-2.55

-1.12

-1.36

-1.27

-1.36

EPS Diluted

-7.22

-1.50

-1.67

-1.50

-2.55

-1.12

-1.36

-1.27

-1.36

Weighted Average Basic Shares

132.09M

123.27M

122.02M

119.98M

119.46M

118.50M

118.08M

117.69M

Weighted Average Diluted Shares

132.09M

123.27M

122.43M

119.98M

119.46M

118.50M

118.08M

117.69M

Annual Report	12/31/2025	12/31/2024	12/31/2023	12/31/2022	12/31/2021	12/31/2020	12/31/2019	12/31/2018
Revenue	88.04M	18.47M	7.53M	94.59M	70.43M	55.83M	26.87M	31.50M
Cost of Goods Sold	10.13M	339.41M	330.12M	240.81M	159.94M	96.95M	86.13M	89.14M
Gross Profit	77.91M	-320.93M	-322.59M	-146.22M	-89.51M	-41.12M	-59.26M	-57.63M
Gross Profit Margin	88.5%	-1737.2%	-4284.1%	-154.6%	-127.1%	-73.7%	-220.5%	-183.0%
Total Operating Expenses	690.17M	215.31M	173.61M	177.98M	96.80M	52.82M	39.61M	31.28M
Research & Development	405.90M	339.41M	330.12M	240.81M	159.94M	96.95M	86.13M	89.14M
Selling, General & Administrative	284.27M	215.31M	173.61M	177.98M	96.80M	52.82M	39.61M	31.28M
Operating Income (EBIT)	-612.26M	-536.25M	-496.20M	-324.20M	-186.31M	-93.94M	-98.87M	-88.92M
Operating Margin	-695.4%	-2902.7%	-6589.7%	-342.8%	-264.5%	-168.3%	-368.0%	-282.3%
Income Before Tax (EBT)	-784.96M	-589.53M	-526.24M	-388.95M	-215.31M	-127.29M	-121.69M	-106.29M
Interest Income	48.42M	51.53M	27.63M	11.34M	331K	5.33M	4.54M	4.19M
Interest Expense	103.87M	86.51M	57.67M	51.16M	29.33M	38.68M	27.36M	21.56M
Other Income/Expense	-172.70M	-53.28M	-30.04M	-64.75M	-29.00M	-33.35M	-22.82M	-17.37M
Net Income	-784.96M	-589.53M	-526.24M	-388.95M	-215.31M	-127.29M	-121.69M	-106.29M
Income Tax Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Net Profit Margin	-891.6%	-3191.1%	-6988.6%	-411.2%	-305.7%	-228.0%	-452.9%	-337.4%
EBITDA	-602.57M	-526.72M	-484.31M	-315.80M	-176.68M	-92.11M	-97.57M	-87.68M
EBITDA Margin	-684.4%	-2851.1%	-6431.8%	-333.9%	-250.9%	-165.0%	-363.2%	-278.3%
Depreciation & Amortization	9.69M	9.53M	11.89M	8.40M	9.64M	1.83M	1.29M	1.24M
EPS Basic	-6.54	-5.26	-5.45	-4.33	-2.80	-1.97	-2.59	-1.95
EPS Diluted	-6.54	-5.26	-5.45	-4.33	-2.80	-1.97	-2.59	-1.95
Weighted Average Basic Shares	120.02M	111.98M	96.52M	89.83M	76.89M	64.52M	57.58M	54.42M
Weighted Average Diluted Shares	120.10M	111.98M	96.52M	89.83M	76.89M	64.52M	57.58M	54.42M

Annual Report

12/31/2025

12/31/2024

12/31/2023

12/31/2022

12/31/2021

12/31/2020

12/31/2019

12/31/2018

Revenue

88.04M

18.47M

7.53M

94.59M

70.43M

55.83M

26.87M

31.50M

Cost of Goods Sold

10.13M

339.41M

330.12M

240.81M

159.94M

96.95M

86.13M

89.14M

Gross Profit

77.91M

-320.93M

-322.59M

-146.22M

-89.51M

-41.12M

-59.26M

-57.63M

Gross Profit Margin

88.5%

-1737.2%

-4284.1%

-154.6%

-127.1%

-73.7%

-220.5%

-183.0%

Total Operating Expenses

690.17M

215.31M

173.61M

177.98M

96.80M

52.82M

39.61M

31.28M

Research & Development

405.90M

339.41M

330.12M

240.81M

159.94M

96.95M

86.13M

89.14M

Selling, General & Administrative

284.27M

215.31M

173.61M

177.98M

96.80M

52.82M

39.61M

31.28M

Operating Income (EBIT)

-612.26M

-536.25M

-496.20M

-324.20M

-186.31M

-93.94M

-98.87M

-88.92M

Operating Margin

-695.4%

-2902.7%

-6589.7%

-342.8%

-264.5%

-168.3%

-368.0%

-282.3%

Income Before Tax (EBT)

-784.96M

-589.53M

-526.24M

-388.95M

-215.31M

-127.29M

-121.69M

-106.29M

Interest Income

48.42M

51.53M

27.63M

11.34M

331K

5.33M

4.54M

4.19M

Interest Expense

103.87M

86.51M

57.67M

51.16M

29.33M

38.68M

27.36M

21.56M

Other Income/Expense

-172.70M

-53.28M

-30.04M

-64.75M

-29.00M

-33.35M

-22.82M

-17.37M

Net Income

-784.96M

-589.53M

-526.24M

-388.95M

-215.31M

-127.29M

-121.69M

-106.29M

Income Tax Expense

0.00

Net Profit Margin

-891.6%

-3191.1%

-6988.6%

-411.2%

-305.7%

-228.0%

-452.9%

-337.4%

EBITDA

-602.57M

-526.72M

-484.31M

-315.80M

-176.68M

-92.11M

-97.57M

-87.68M

EBITDA Margin

-684.4%

-2851.1%

-6431.8%

-333.9%

-250.9%

-165.0%

-363.2%

-278.3%

Depreciation & Amortization

9.69M

9.53M

11.89M

8.40M

9.64M

1.83M

1.29M

1.24M

EPS Basic

-6.54

-5.26

-5.45

-4.33

-2.80

-1.97

-2.59

-1.95

EPS Diluted

-6.54

-5.26

-5.45

-4.33

-2.80

-1.97

-2.59

-1.95

Weighted Average Basic Shares

120.02M

111.98M

96.52M

89.83M

76.89M

64.52M

57.58M

54.42M

Weighted Average Diluted Shares

120.10M

111.98M

96.52M

89.83M

76.89M

64.52M

57.58M

54.42M

Income Statement

Quarterly Income Statement (USD)

Annual Income Statement (USD)